rss Posted April 21, 2019 Report Share Posted April 21, 2019 Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases. Nanomedicine. 2019 Apr 17;: Authors: Espinoza LC, Silva-Abreu M, Calpena AC, Rodríguez-Lagunas MJ, Fábrega MJ, Garduño-Ramírez ML, Clares B Abstract Pioglitazone (PGZ) is a peroxisome proliferator-activated receptor agonist. Its role in the inflammatory response modulation opens the door for additional therapeutic applications. The purpose of this study was to develop a pioglitazone nanoemulsion (PGZ-NE) to investigate its anti-inflammatory efficacy on the skin. For that a NE vehicle aimed for skin delivery was optimized and characterized. The resulting PGZ-NE showed a good anti-inflammatory efficacy by decreasing the expression of adipose inflammatory cytokines IL-6, IL-1β and TNF-α. The properties of the developed nanocarrier allowed achieving a high permeation flux of PGZ through the skin as well as high retained amount in the skin, probably due to the depot effect of ingredients, which assured a prolonged local action, with good skin tolerability among participating individuals. Consequently, these results suggest that PGZ-NE may be used as an alternative treatment for inflammatory skin diseases such as rosacea, atopic dermatitis or psoriasis. PMID: 31004811 [PubMed - as supplied by publisher] {url} = URL to article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now